ALPX, an EMBL spin-off, provides comprehensive structural biology services to accelerate drug discovery programs. They specialize in delivering rapid and reliable structural insights for biotech and pharmaceutical partners, leveraging their expertise across X-ray crystallography, cryo-EM, and protein production.
Their core strength lies in their integrated, transparent, and flexible high-throughput protein-to-structure pipelines, designed to address challenging targets and timelines.

• X-ray Crystallography: ALPX offers end-to-end services from protein crystallization to structure determination, including compound and fragment screening. ALPX’s operations are supported by proprietary technologies like CrystalDirect™ and CRIMS and enabled by weekly access to synchrotron beamlines, ensuring swift delivery of high-quality data.

• Cryo-EM: ALPX provides a streamlined workflow from sample preparation and grid screening to data collection and high-resolution structure determination. Their process is supported by collaborations with leading imaging centers and robust cloud-based processing infrastructure, allowing them to manage complex projects efficiently.

• Protein Production: ALPX delivers optimized protein expression and purification services tailored for downstream structural studies. Their deep understanding of diverse protein targets ensures the production of high-quality material, which is a critical foundation for successful structural campaigns.

ALPX has extensive experience in solving structures for challenging targets and complex systems such as large protein complexes, molecular glues and PROTACs, protein-antibody and protein-DNA complexes and membrane proteins. Their automated platforms and deep scientific expertise enable them to deliver structural data with speed and precision, helping their partners advance their projects from early hits to validated lead candidates.